Journal of Brain And Spinal Cancer

The Open Access Pub has the reputation for quick reviewing and publishing original research articles. The editorial boards of our journals have many dedicated and reputed scientists as editorial members. Their support helps many researchers from all countries to enhance their research between scientists of various communities. This platform plays a crucial role in promoting science networks and exchanges.

Brain And Spinal Cancer-Radiation Oncology-Pranshu Mohindra


Assistant Professor,
Radiation Oncology.


Send an Email

Pranshu Mohindra


University of Maryland School of Medicine,
655 W. Baltimore Street,
Baltimore MD 21201.

Research Interests:

  • Radiation Oncology
  • Head and Neck Cancer
  • Brain and Spinal Cancer
  • Lung Cancer
  • Gynecological Cancer
  • Normal tissue radiation injury and toxicity


  • Dr. Mohindra has received several academic excellence, research and travel awards during his residency including the 2014 Radiological Society of North America (RSNA) Roentgen Resident/Fellow Award for outstanding radiologic research and the 2014 American Society for Radiation Oncology (ASTRO) Resident Digital Poster Discussion Award in the Biology category. 
  • He also served as the Chief resident for the year 2013-14. 
  • Dr. Mohindra has active involvement in multi-disciplinary collaborative research endeavors including prospective clinical protocols with special emphasis on early phase clinical trials evaluating both radiation sensitizers and radiation toxicity mitigators or evaluation of modern radiation techniques. 
  • He currently serve as national PI of two NCI-sponsored phase-I clinical trials; one of which was career development project team award evaluating a novel DNA repair pathway inhibitor with whole brain radiotherapy (WBRT) in patients with brain metastases from NSCLC (CIRB and CTEP approved, NCT02589522). 
  • The other phase-I clinical trial evaluating combination of oral 5-iodo-2-pyrimidinone-2-deoxyribose (IPdR) with WBRT in brain metastases (CTEP approved, CIRB review pending). 
  • He is also a co-PI for an ongoing phase Iab dose escalation study evaluating the safety and efficacy of neoadjuvant stereotactic body radiation therapy (SBRT) with concomitant capecitabine for resectable pancreatic carcinoma (NCT01918644) and a co-investigator on an ongoing phase II clinical study evaluating the role of pulsed-reduced dose-rate (PRDR) radiation therapy with bevacizumab for recurrent highgrade gliomas (University of Wisconsin Hospital and Clinics, NCT01743950). 
  • He was also recently appointed as national Radiation Oncology Co-Chair on an Alliance for Clinical Trials in Oncology Clinical trial (ALLIANCE A041501) that is currently under development.
  • Dr. Mohindra is an appointed member of the ACR Radiation Oncology In-Training (TXITTM) Exam committee developing examination questions for residents in radiation oncology. 
  • He served as an appointed member of committees within the American Society for Radiation Oncology (ASTRO) and Alliance for Clinical Trials in Oncology.